Interplay between HGF/SF-Met-Ras signaling, tumor metabolism and blood flow as a potential target for breast cancer therapy

Oncoscience

Volumn 1, Issue 1, 2014, Pages 30-38

  Natan, Sari ^a   Tsarfaty, Galia ^b   Horev, Judith ^a   Haklai, Roni ^a   Kloog, Yoel ^a   Tsarfaty, Ilan ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

Functional molecular imaging; HGF Met Ras as targets for therapy; Tumor metabolism

Indexed keywords

EID: 84906244653     PISSN: None     EISSN: 23314737     Source Type: Journal    
DOI: 10.18632/oncoscience.6     Document Type: Article

References (40)

1. Jain RK. Antiangiogenic therapy for cancer: current and emerging concepts. Oncology (Williston Park). 2005; 19(4 Suppl 3): 7-16.
2. MankoffDA, Dunnwald LK, Partridge SC and Specht JM. Blood flow-metabolism mismatch: good for the tumor, bad for the patient. Clin Cancer Res. 2009; 15(17): 5294-5296.
3. Gherardi E, Birchmeier W, Birchmeier C and Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012; 12(2): 89-103.
4. Birchmeier C, Birchmeier W, Gherardi E and Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003; 4(12): 915-925.
5. Gibney GT, Aziz SA, Camp RL, Conrad P, Schwartz BE, Chen CR, Kelly WK and Kluger HM. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Ann Oncol. 24(2): 343-349.
6. Goyal L, Muzumdar MD and Zhu AX. Targeting the HGF/c-MET Pathway in Hepatocellular Carcinoma. Clin Cancer Res. 19(9): 2310-2318.
7. Ponzo MG, Lesurf R, Petkiewicz S, O'Malley FP, Pinnaduwage D, Andrulis IL, Bull SB, Chughtai N, Zuo D, Souleimanova M, Germain D, Omeroglu A, CardiffRD, Hallett M and Park M. Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc Natl Acad Sci U S A. 2009; 106(31): 12903-12908.
8. Kaposi-Novak P, Lee JS, Gomez-Quiroz L, Coulouarn C, Factor VM and Thorgeirsson SS. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest. 2006; 116(6): 1582-1595.
9. Underiner TL, Herbertz T and Miknyoczki SJ. Discovery of small molecule c-Met inhibitors: Evolution and profiles of clinical candidates. Anticancer Agents Med Chem. 2010; 10(1): 7-27.
10. Rodig SJ and Shapiro GI. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases. Curr Opin Investig Drugs. 11(12): 1477-1490.
11. Kaplan O, Firon M, Vivi A, Navon G and Tsarfaty I. HGF/SF activates glycolysis and oxidative phosphorylation in DA3 murine mammary cancer cells. Neoplasia. 2000; 2(4): 365-377.
12. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S and Comoglio PM. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer cell. 2003; 3(4): 347-361.
13. Tsarfaty G, Stein GY, Moshitch-Moshkovitz S, Kaufman DW, Cao B, Resau JH, Vande Woude GF and Tsarfaty I. HGF/SF increases tumor blood volume: a novel tool for the in vivo functional molecular imaging of Met. Neoplasia. 2006; 8(5): 344-352.
14. Shaharabany M, Abramovitch R, Kushnir T, Tsarfaty G, Ravid-Megido M, Horev J, Ron R, Itzchak Y and Tsarfaty I. In vivo molecular imaging of met tyrosine kinase growth factor receptor activity in normal organs and breast tumors. Cancer research. 2001; 61(12): 4873-4878.
15. Gao CF and Vande Woude GF. HGF/SF-Met signaling in tumor progression. Cell Res. 2005; 15(1): 49-51.
16. Gaglio D, Metallo CM, Gameiro PA, Hiller K, Danna LS, Balestrieri C, Alberghina L, Stephanopoulos G and Chiaradonna F. Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth. Mol Syst Biol. 2011; 7: 523.
17. Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, Fletcher-Sananikone E, Locasale JW, Son J, Zhang H, ColoffJL, Yan H, Wang W, Chen S, Viale A, Zheng H, Paik JH, et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell. 149(3): 656-670.
18. Chapman MS and Miner JN. Novel mitogen-activated protein kinase kinase inhibitors. Expert Opin Investig Drugs. 2011; 20(2): 209-220.
19. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M and Varmus H. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004; 101(36): 13306-13311.
20. Danilkovitch-Miagkova A and Zbar B. Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J Clin Invest. 2002; 109(7): 863-867.
21. Deberardinis RJ, Sayed N, Ditsworth D and Thompson CB. Brick by brick: metabolism and tumor cell growth. Current opinion in genetics & development. 2008; 18(1): 54-61.
22. Mor A, Aizman E, George J and Kloog Y. Ras inhibition induces insulin sensitivity and glucose uptake. PLoS One. 6(6): e21712.
23. Aharonson Z, Gana-Weisz M, Varsano T, Haklai R, Marciano D and Kloog Y. Stringent structural requirements for anti-Ras activity of S-prenyl analogues. Biochim Biophys Acta. 1998; 1406(1): 40-50.
24. Kloog Y and Cox AD. Prenyl-binding domains: potential targets for Ras inhibitors and anti-cancer drugs. Semin Cancer Biol. 2004; 14(4): 253-261.
25. Kloog Y and Cox AD. RAS inhibitors: potential for cancer therapeutics. Mol Med Today. 2000; 6(10): 398-402.
26. Blum R and Kloog Y. Tailoring Ras-pathway-inhibitor combinations for cancer therapy. Drug Resist Updat. 2005; 8(6): 369-380.
27. Yaari S, Jacob-Hirsch J, Amariglio N, Haklai R, Rechavi G and Kloog Y. Disruption of cooperation between Ras and MycN in human neuroblastoma cells promotes growth arrest. Clin Cancer Res. 2005; 11(12): 4321-4330.
28. Blum R, Jacob-Hirsch J, Amariglio N, Rechavi G and Kloog Y. Ras inhibition in glioblastoma down-regulates hypoxiainducible factor-1alpha, causing glycolysis shutdown and cell death. Cancer research. 2005; 65(3): 999-1006.
29. Goldberg L and Kloog Y. A Ras inhibitor tilts the balance between Rac and Rho and blocks phosphatidylinositol 3-kinase-dependent glioblastoma cell migration. Cancer research. 2006; 66(24): 11709-11717.
30. Jansen B, Schlagbauer-Wadl H, Kahr H, Heere-Ress E, Mayer BX, Eichler H, Pehamberger H, Gana-Weisz M, Ben-David E, Kloog Y and WolffK. Novel Ras antagonist blocks human melanoma growth. Proc Natl Acad Sci U S A. 1999; 96(24): 14019-14024.
31. Goldberg L, Israeli R and Kloog Y. FTS and 2-DG induce pancreatic cancer cell death and tumor shrinkage in mice. Cell Death Dis. 2012; 3: e284.
32. Laheru D, Shah P, Rajeshkumar NV, McAllister F, Taylor G, Goldsweig H, Le DT, Donehower R, Jimeno A, Linden S, Zhao M, Song D, Rudek MA and Hidalgo M. Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer. Investigational new drugs. 2012; 30(6): 2391-2399.
33. Aizman E, Mor A, Levy A, George J and Kloog Y. Ras inhibition by FTS attenuates brain tumor growth in mice by direct antitumor activity and enhanced reactivity of cytotoxic lymphocytes. Oncotarget. 2012; 3(2): 144-157.
34. Santen RJ, Lynch AR, Neal LR, McPherson RA and Yue W. Farnesylthiosalicylic acid: inhibition of proliferation and enhancement of apoptosis of hormone-dependent breast cancer cells. Anticancer Drugs. 2006; 17(1): 33-40.
35. Firon M, Shaharabany M, Altstock RT, Horev J, Abramovici A, Resau JH, Vande Woude GF and Tsarfaty I. Dominant negative Met reduces tumorigenicity-metastasis and increases tubule formation in mammary cells. Oncogene. 2000; 19(20): 2386-2397.
36. Haklai R, Elad-Sfadia G, Egozi Y and Kloog Y. Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice. Cancer Chemother Pharmacol. 2008; 61(1): 89-96.
37. Zundelevich A, Elad-Sfadia G, Haklai R and Kloog Y. Suppression of lung cancer tumor growth in a nude mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid). Mol Cancer Ther. 2007; 6(6): 1765-1773.
38. Feigl EO. Berne's adenosine hypothesis of coronary blood flow control. Am J Physiol Heart Circ Physiol. 2004; 287(5): H1891-1894.
39. Song CW, Park HJ, Lee CK and Griffin R. Implications of increased tumor blood flow and oxygenation caused by mild temperature hyperthermia in tumor treatment. Int J Hyperthermia. 2005; 21(8): 761-767.
40. Fu Y, Watson G, Jimenez JJ, Wang Y and Lopez DM. Expansion of Immunoregulatory Macrophages by Granulocyte-Macrophage Colony-stimulating Factor Derived from a Murine Mammary Tumor. Cancer Res. 1990; 50: 227-234.